BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26369969)

  • 1. Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.
    Farooqui A; Huang L; Wu S; Cai Y; Su M; Lin P; Chen W; Fang X; Zhang L; Liu Y; Zeng T; Paquette SG; Khan A; Kelvin AA; Kelvin DJ
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7255-64. PubMed ID: 26369969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir.
    Ge Y; Chi Y; Min X; Zhao K; Wu B; Wu T; Zhu X; Shi Z; Zhu F; Cui L
    Virology; 2019 Oct; 536():58-67. PubMed ID: 31400550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
    Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.
    Cao RY; Xiao JH; Cao B; Li S; Kumaki Y; Zhong W
    Antivir Chem Chemother; 2014 Dec; 23(6):237-40. PubMed ID: 23948557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Farrukee R; Butler J; Reading PC; Hurt AC
    Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
    Tran-To Su C; Ouyang X; Zheng J; Kwoh CK
    BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
    Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Yoshinaga T; Naito A; Sato A
    Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.
    Tanaka A; Nakamura S; Seki M; Iwanaga N; Kajihara T; Kitano M; Homma T; Kurihara S; Imamura Y; Miyazaki T; Izumikawa K; Kakeya H; Yanagihara K; Kohno S
    Antivir Ther; 2015; 20(1):11-9. PubMed ID: 24517996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
    Tang J; Gao R; Liu L; Zhang S; Liu J; Li X; Fang Q; Feng Z; Xu C; Huang W; Wang D
    Sci Rep; 2021 Aug; 11(1):16293. PubMed ID: 34381119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
    Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.
    Kitano M; Kodama M; Itoh Y; Kanazu T; Kobayashi M; Yoshida R; Sato A
    Antimicrob Agents Chemother; 2013 May; 57(5):2286-94. PubMed ID: 23478960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.
    Baranovich T; Jones JC; Russier M; Vogel P; Szretter KJ; Sloan SE; Seiler P; Trevejo JM; Webby RJ; Govorkova EA
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2118-31. PubMed ID: 26787699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
    Hai R; Schmolke M; Leyva-Grado VH; Thangavel RR; Margine I; Jaffe EL; Krammer F; Solórzano A; García-Sastre A; Palese P; Bouvier NM
    Nat Commun; 2013; 4():2854. PubMed ID: 24326875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
    Bantia S; Upshaw R; Babu YS
    Antiviral Res; 2011 Sep; 91(3):288-91. PubMed ID: 21722670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
    Tomozawa T; Hoshino K; Yamashita M; Kubo S
    J Infect Chemother; 2019 Aug; 25(8):584-588. PubMed ID: 30935767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.
    Bantia S; Kellogg D; Parker C; Upshaw R; Ilyushina NA; Babu YS
    Antiviral Res; 2011 Apr; 90(1):17-21. PubMed ID: 21316393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
    Zhang Y; Gao H; Liang W; Tang L; Yang Y; Wu X; Yu L; Chen P; Zheng S; Ou H; Li L
    BMC Infect Dis; 2016 Feb; 16():76. PubMed ID: 26864456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.
    Ranadheera C; Hagan MW; Leung A; Collignon B; Cutts T; Theriault S; Embury-Hyatt C; Kobasa D
    J Virol; 2016 Nov; 90(21):9931-9941. PubMed ID: 27558428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.